Ipilimumab 12-month Intensive Pharmacovigilance Protocol
Phase of Trial: Phase IV
Latest Information Update: 25 May 2015
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 22 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.